The other diagnosis predictors selected by at least two models were: the number of pharmacy claims related to agents acting on the renin-angiotensin system (II level ATC: C09), diuretics (II level ATC: C03), antibacterials for systemic use (II level ATC: J01) and thyroid therapy (II level ATC: H03); the presence of cardiomyopathy and diabetes as comorbidities; the presence of co-payment exemption codes related to permanent disability and hypertensive disease without organ damage; the request for chest CT scan, electrocardiogram, cortisol level dosing, and free thyroxine level dosing (Fig. 2). This evidence concerns the gene REN and cardiomyopathy.